How do you know if a “positive” study is positive? And what if clinical trial participants unionized?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into Biogen’s much-dissected data on a treatment for Alzheimer’s disease, with on-the-ground takes from experts at a scientific conference. Then, STAT’s Eric Boodman joins us to spin a drug-discovery yarn involving one-eyed sheep, Basque farmers, and the quest to treat a rare form of cancer.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I live in Singapore, age 70 and via brain scan found to have amyloid protein in my brain hence my upmost concern and worries and would appreciate any comments or useful feedback

Your daily dose of news in health and medicine

Privacy Policy